New cancer drug enters first human trials for advanced tumors
NCT ID NCT06234397
Summary
This is the first human study testing a new cancer drug called BH3120, both alone and combined with an existing immunotherapy drug (pembrolizumab). The trial aims to find safe doses and see if the treatment helps control advanced solid tumors that have spread or can't be removed by surgery. Researchers will enroll 245 adults with various cancers who have no other standard treatment options available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center
RECRUITINGCincinnati, Ohio, 45219, United States
-
Mary Crowley Cancer Research
WITHDRAWNDallas, Texas, 75230, United States
-
Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cencer Center
RECRUITINGSan Antonio, Texas, 78229, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital
RECRUITINGSeoul, 03722, South Korea
-
The START Center for Cancer Care - Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Conditions
Explore the condition pages connected to this study.